Being heard on all-oral therapy for resistant tuberculosis

Affiliations

¹ Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, USA. Electronic address: jennifer_furin@hms.harvard.edu.
² Southern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa.

Comment

Jennifer Furin et al. Lancet Infect Dis. 2022 Jul.

. 2022 Jul;22(7):923-924.

doi: 10.1016/S1473-3099(22)00027-5. Epub 2022 May 2.

¹ Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, USA. Electronic address: jennifer_furin@hms.harvard.edu.
² Southern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa.

No abstract available

Conflict of interest statement

We declare no competing interests.

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
Ndjeka N, Campbell JR, Meintjes G, Maartens G, Schaaf HS, Hughes J, Padanilam X, Reuter A, Romero R, Ismail F, Enwerem M, Ferreira H, Conradie F, Naidoo K, Menzies D. Ndjeka N, et al. Lancet Infect Dis. 2022 Jul;22(7):1042-1051. doi: 10.1016/S1473-3099(21)00811-2. Epub 2022 May 2. Lancet Infect Dis. 2022. PMID: 35512718 Free PMC article.